Clinical Trial Update: Study of Low-Dose Cytarabine and Etoposide With or Without All-Trans Retinoic Acid in Older Patients Not Eligible for Intensive Chemotherapy With Acute Myeloid Leukemia and NPM1 Mutation [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating low-dose cytarabine and etoposide with or without all-trans retinoic acid in older AML patients not eligible for intensive chemotherapy…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• All-trans Retinoic Acid (all-trans retinoic acid)
• Etoposide (Etoposide)
• Low-dose cytarabine (Cytarabine (low-dose))

Snippet

Sponsor: University of Ulm | Conditions: Acute Myeloid Leukemia (AML) | Phase 3 | Status: COMPLETED